SCHEMBL4095004

SCHEMBL4095004

Cc1ccc(CCNc2ccc(O)c(C(=O)O)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 3/20 0.56
PPARA Q07869 1/20 0.55
STING1 Q86WV6 1/20 0.55
CSNK2A1 P68400 1/20 0.53
MCL1 Q07820 4/20 0.51
ALDH1A1 P00352 4/20 0.50
MAPT P10636 3/20 0.50
NOX4 Q9NPH5 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
LCK P06239 2/20 0.50
RGS12 O14924 1/20 0.50
EGFR P00533 1/20 0.50
CAMKK2 Q96RR4 1/20 0.50
POLB P06746 1/20 0.50
PKM P14618 1/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
BCL2L1 Q07817 1/20 0.48
BCL2A1 Q16548 1/20 0.48
KLKB1 P03952 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL608860 0.92 MCL1 (0.58) KDM4CPPARASTING1CSNK2A1MCL1
SCHEMBL608754 0.87 NOX4 (0.61) KDM4CPPARASTING1MCL1ALDH1A1
SCHEMBL12863172 0.86 EGFR (0.55) MAPTNOX4EGFRSYK
SCHEMBL610123 0.86 SYK (0.58) KDM4CPPARASTING1MCL1ALDH1A1
SCHEMBL29388077 0.86 SYK (0.58) KDM4CPPARASTING1MCL1ALDH1A1
SCHEMBL609252 0.85 SYK (0.60) KDM4CPPARASTING1ALDH1A1MAPT
SCHEMBL4098010 0.85 NOX4 (0.50) KDM4CPPARASTING1CSNK2A1MCL1
SCHEMBL608498 0.84 KDM4C (0.53) KDM4CPPARASTING1MCL1ALDH1A1
SCHEMBL4116154 0.83 KDM4C (0.52) KDM4CPPARASTING1MCL1ALDH1A1
SCHEMBL29391594 0.82 PPARA (0.57) KDM4CPPARASTING1MCL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120301551-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2012-11-29 US disclosed
US-20120209025-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GWAG BYOUNG-JOO (KR) 2012-08-16 US disclosed
US-20110028757-A1 MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2011-02-03 US disclosed
US-20090149542-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2009-06-11 US disclosed
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149542-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION BCL2, BAX, SMN1; SMN2 KDM4C 3544/4885PPARA 1265/4885STING1 3945/4885
US-20120301551-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION BCL2, BAX, SMN1; SMN2 KDM4C 3544/4885PPARA 1265/4885STING1 3945/4885
US-20120209025-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B KDM4C 4051/4885PPARA 223/4885STING1 3665/4885
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction BCL2, BAX, SMN1; SMN2 KDM4C 3544/4885PPARA 1265/4885STING1 3945/4885
US-20110028757-A1 MANUFACTURING METHOD OF 2-HYDROXY-5-PHENYLALKYLAMINOBENZOIC ACID DERIVATIVES AND THEIR SALTS PAH, HACL2, HAAO KDM4C 451/4885PPARA 685/4885STING1 4694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.